Bausch + Lomb was valued at $6.48 billion in the company’s U.S. market debut on May 6 as the eye-care company’s shares opened nearly 3 percent above an offer price that was well below the targeted range.

AbbVie’s Allergan announced that VUITY, the company’s unique treatment for presbyopia, received approval from the U.S. Food and Drug Administration as the first eye drop to be approved for the condition.

International eye-care products manufacturer Allergan announced positive outcomes from the AbbVie company’s Phase 3 study of a new treatment for presbyopia, as the ophthalmic solution AGN-190584 met primary and key secondary endpoints.

Drugmaker Aerie Pharmaceuticals Inc said on Wednesday its experimental eye drop met the main goal of a late-stage study, sending its shares up as much as 65 percent in extended trading. The drug, Rhopressa, showed that it was not inferior to a commonly prescribed treatment, timolol, in reducing pressure inside the eye in patients suffering […]